Another Brick in the Wall: A New Federally Funded Study on Cannabis and the Opioid Crisis (2026)
Another Brick in the Wall: A New Federally Funded Study on Cannabis and the Opioid Crisis
A new study funded by both the U.S. National Institutes of Health and its Canadian counterpart found that people using cannabis to manage opioid withdrawal reported using significantly fewer opioids. Among those in serious pain, the effect was more than six times stronger. Here’s what the research says, and where the honest boundaries are.
The opioid crisis is one of the great American tragedies of the last quarter century. It has killed hundreds of thousands of people, hollowed out communities, and touched almost every family in the country in one way or another, directly or through someone they love. It did not happen because people are weak. It happened because powerful, dangerous drugs got prescribed and distributed at massive scale, and because the transition from a prescription bottle to a street supply laced with fentanyl is a shorter and more lethal path than most people realize. Any research that points toward a way of reducing that harm deserves a careful, serious look.
A new study, published in the Journal of Cannabis Research, adds another data point to a question researchers have been circling for years: can cannabis help people reduce their reliance on opioids? This particular study looked at one of the hardest-hit populations imaginable, and its findings are worth understanding both for what they show and for what they carefully do not claim.
What the Study Actually Found
Researchers from the University of British Columbia, Simon Fraser University, and UCLA surveyed 197 people in Vancouver who reported using both cannabis and unregulated opioids, meaning street drugs like fentanyl or heroin rather than prescription medications. This is a population at extreme risk, and studying it directly is difficult and important work. You can read the full study in the Journal of Cannabis Research if you want the complete methodology and data.
About 45 percent of the participants said they had used cannabis to manage opioid withdrawal symptoms in the past six months. Of those, roughly 66 percent agreed that when they used cannabis, they didn’t need to consume as much of the opioids they were taking. After adjusting for factors like age, gender, race, and pain levels, the researchers found that using cannabis to manage withdrawal was associated with more than twice the odds of reporting reduced opioid use.
The effect got dramatically stronger among people in serious pain. For participants experiencing moderate or severe pain, those who used cannabis for withdrawal had more than six times the odds of reducing their opioid consumption compared to those who didn’t. Overall, about 57 percent of participants said they used fewer opioids during periods when they were using cannabis. The study authors summarized it plainly: “Cannabis use for opioid withdrawal was significantly associated with self-reported reductions in opioid use.”
What makes this study notable is that it’s the first quantitative analysis to specifically examine the relationship between intentionally using cannabis for opioid withdrawal and actual changes in how much opioid people subsequently consumed. Earlier research had looked at whether cannabis could treat individual withdrawal symptoms like pain, anxiety, and insomnia, and other studies had examined cannabis and opioid cravings. This one connected the dots between intentional withdrawal management and downstream reduction in use. It was funded by both the U.S. National Institutes of Health and the Canadian Institutes of Health Research, which is to say this is serious, government-backed science, not industry marketing.
The Honest Boundaries, Stated Up Front
Now for the part that a responsible brand has to say clearly, because the subject matter is serious and the stakes are life and death. This study looked at a specific, high-risk population using street opioids in a harm-reduction context. It is not a claim that any cannabis product, including anything we make, is a treatment for opioid addiction or withdrawal. It is observational research showing an association, and the authors themselves were careful to call for controlled experimental trials to test the relationship properly.
If you or someone you love is struggling with opioid dependency, the right move is not a hemp gummy from any company. The right move is professional medical help. Opioid use disorder is a serious medical condition with established, evidence-based treatments, and there are people whose entire job is to help with exactly this. We will never position our products as a substitute for that care, because doing so would be dishonest and potentially dangerous. What this study does is add to a growing body of evidence that the medical and research community is taking seriously, and that evidence points toward cannabis having a legitimate role in the broader conversation about reducing opioid harm. That’s meaningful. It’s also not the same thing as a product recommendation, and we won’t pretend otherwise.
With that boundary clearly drawn, the study’s authors made a point that transcends the specific population they studied. “Cannabis is associated with markedly lower risks of morbidity and mortality compared to unregulated opioids.” That comparison is the heart of why this research matters at the public-health level. Whatever cannabis’s own risks are, and they are real, they exist on a completely different scale from the risks of street fentanyl. For a population already using the latter, the harm-reduction math is stark.
This Isn’t One Study. It’s a Wall Being Built One Brick at a Time.
The reason this new study matters is not that it stands alone. It’s that it fits into a pattern that has been getting steadily more consistent and harder to dismiss. Over the past several years, study after study has pointed in the same direction, using different populations, different methods, and different research teams, and arriving at broadly similar conclusions. When independent researchers keep finding the same signal from different angles, that’s when a hypothesis starts becoming an understanding.
Consider the recent research we’ve covered on this topic. A five-year study of 241 treatment-refractory chronic lower back pain patients found that opioid use in that group fell from 100 percent to under 5 percent over the study period. A separate study of more than 3,500 patients found that medical cannabis helped people reduce their use of opioids, sleeping aids, and antidepressants, with fewer side effects after switching. A federally funded study found that states legalizing cannabis saw significant reductions in opioid overdoses among adults with employer-sponsored insurance, suggesting a substitution effect. Multiple studies published by the American Medical Association have found cannabis serving as an effective opioid substitute in chronic pain treatment.
The population-level research is just as striking. One study found a consistent negative relationship between cannabis legalization and fatal opioid overdoses, with stronger effects in states that legalized earlier in the crisis, estimating a decrease of roughly 3.5 overdose deaths per 100,000 people. Research on Utah following its medical cannabis legalization found reductions in both opioid use by chronic pain patients and prescription overdose deaths statewide. Even the money side shows it: one study found that medical cannabis legalization was associated with reduced payments from opioid manufacturers to pain doctors, with the authors attributing the decline to cannabis becoming available as a substitute.
No single one of these studies proves causation on its own. Observational research rarely can. But the accumulation is what matters. When this many careful studies, funded by governments and published in peer-reviewed journals, keep finding the same pattern, the responsible conclusion is not to dismiss it. It’s to take it seriously and keep investigating, which is exactly what the research community is doing.
Why Cannabinoids Affect Pain in the First Place
The underlying reason cannabis shows up in all this pain and opioid research has to do with the endocannabinoid system, the internal signaling network that runs throughout your body and helps regulate pain, inflammation, mood, sleep, and stress. THC and CBD interact with that system through what are called CB1 and CB2 receptors, influencing how pain signals get processed and how the body manages the emotional and physical weight of chronic discomfort. Crucially, that mechanism operates regardless of how the cannabinoids get into your body. A gummy, a tincture, a topical, or any other format engages the same underlying biology. The receptors respond to the cannabinoids, not to the delivery method.
This matters for everyday people because most folks managing everyday aches and pains are not looking to smoke anything. They want something clean, measured, and easy to fit into a normal working life. And the good news is that the cannabinoid science applies across the whole range of product formats. What changes between a gummy and a topical is not whether the cannabinoids work, but how fast they take effect, how long they last, and whether the effect is localized to one area or distributed throughout the body. Those differences are exactly what let you match the right format to the right kind of discomfort.
Where Workman’s Relief Fits, Honestly and Within Our Lane
Let’s be crystal clear about what we do and don’t claim. Workman’s Relief makes federally legal, hemp-derived wellness products for everyday people dealing with everyday discomfort. We do not make, and would never market, a treatment for opioid dependency or withdrawal. That’s a serious medical matter that belongs with medical professionals, full stop. What we make is a clean, tested, transparent option for the ordinary muscle and joint wear, the restless nights, and the general end-of-day tension that come with living and working in a body that does real things.
For the sore lower back that comes from a hard day of work, our Elbow Grease CBD topicals deliver cannabinoids right to the tissue that hurts, working locally without anything systemic and without any high. For the general daily wind-down, our CBD gummies, including Punch In for daytime and Punch Out for nighttime, offer a measured, easy-to-dose format that fits into a routine. Our federally compliant D9 THC gummies at a measured 5mg per serving give a predictable, clearly-dosed option for people who want it. And for the pain that keeps you up at night, which is one of the most common reasons people build a cannabinoid routine, the overlap between discomfort and poor sleep is something we covered in depth in our look at how two out of three Americans report cannabis helps them sleep better.
Every one of those products carries a publicly available Certificate of Analysis. The CBD is USDA Certified Organic, grown on Wisconsin soil. Everything is manufactured in-house in our own GMP-certified facility. That matters because in a category where the research is only as good as the product delivering it, knowing exactly what’s in the bottle is the whole game. The studies use precisely measured, verified cannabinoids. A product with unknown potency and unknown contaminants can’t reliably deliver what the science describes. Transparency isn’t a marketing angle for us. It’s the baseline requirement for making a product people can actually trust.
Why This Matters for Working America Specifically
The opioid crisis did not hit every part of the country evenly. It hit working America hardest. The people who do physically demanding jobs are the people most likely to develop chronic pain, most likely to be prescribed opioids for it, and most likely to get caught in the long, brutal cycle that so often follows. Construction workers, warehouse workers, tradespeople, truck drivers, miners, veterans. The map of chronic pain and the map of the opioid epidemic overlap almost perfectly, and that overlap is not a coincidence. It’s the predictable result of hard work on hard bodies meeting a medical system that reached for the prescription pad first.
So when the research keeps suggesting that cannabinoids may have a role to play in reducing opioid reliance, the population that stands to benefit most is exactly the population Workman’s Relief was built to serve. That’s not a sales pitch. It’s an observation about who gets hurt by this crisis and who might have the most to gain from a growing body of evidence pointing toward safer alternatives for managing the chronic pain that starts the whole cycle. The people who build and move and fix things in this country have carried a disproportionate share of the opioid burden. They deserve every legitimate tool that might help.
The study authors themselves framed the stakes in public-health terms, calling for immediate efforts to improve access to legal cannabis, especially for the marginalized populations at highest risk of overdose, as a step toward reducing the health and social harms of opioid use. That’s a research team looking at their own data and concluding that access to a safer alternative could save lives. Whatever your politics, that’s a serious conclusion from serious scientists that deserves to be weighed on its merits.
The Frustrating Policy Backdrop
There is a genuine tension worth naming here, and we’ll name it neutrally. On one hand, the federal government is funding this research. The National Institutes of Health helped pay for the study we’re discussing. That’s the government investing real money to understand whether cannabis can help address a crisis it has spent enormous resources fighting. On the other hand, cannabis remains federally scheduled in a way that makes the research harder to conduct and the access harder to expand, and the policy process for changing that has been slow, contested, and uncertain, as we covered in our look at the DEA’s cannabis rescheduling fight.
That tension, between the government funding the science and the government maintaining the restrictions, is part of the broader messiness we explored in our honest look at why cannabis legalization still feels broken despite overwhelming public support. The country is working through a genuinely complicated issue in real time, through its institutions, at the frustratingly slow pace that big changes usually move. That’s not a knock on anyone in particular. It’s just where things stand. The science is moving faster than the policy, and that gap creates real friction for everyone involved.
The one clear thing amid all that uncertainty is that the federally legal hemp market, operating under the settled 2018 Farm Bill framework, gives everyday Americans access to clean, tested, hemp-derived wellness products right now, without waiting for the larger policy questions to resolve. For the working person dealing with everyday pain who wants a trustworthy option, that access already exists and isn’t dependent on how the scheduling fight breaks.
The Long View
Step back and here’s the arc. The opioid crisis represents one of the most catastrophic public-health failures in modern American history, driven in significant part by the aggressive promotion of powerful, addictive pharmaceuticals. In the shadow of that failure, a growing body of serious, government-funded research keeps pointing toward a plant that humans have used for pain and relief across thousands of years as one possible piece of the solution. There’s a hard irony in that, and there’s also real hope.
The research will keep accumulating. The policy will keep grinding forward at its own pace. And the plant will keep doing what the evidence increasingly suggests it does, whether or not the institutions catch up quickly. For the everyday American, the practical takeaway is simple. The science supporting cannabinoids as a legitimate wellness tool keeps getting stronger, the stigma keeps fading, and the option to choose a clean, tested, federally legal hemp product for everyday discomfort is already on the table.
For our part, we’ll keep making those products the honest way. Lab-tested, USDA Certified Organic, manufactured in America under our own roof, with the lab reports public for anyone to check. We’ll keep serving the working people who carry so much of the physical load in this country, and who have carried more than their share of the opioid burden too. And we’ll keep telling the truth about what our products are and aren’t, because in a category this serious, honesty is the only foundation worth building on.
If you or someone you love is struggling with opioid use, please reach out to a medical professional or a treatment resource. That help is real, and it works. For the everyday aches, the restless nights, and the ordinary wear of a working life, we’re here with something clean and honest whenever you want it.
Browse the full Workman’s Relief lineup →
Subscribe & Save | Veterans & First Responders: 15% Off | View Our Certificates of Analysis | Find a Retail Location
Our Recommendations//
No comment yet, add your voice below!